Enlicitide significantly reduces LDL-C in patients with high cardiovascular risk
Enlicitide significantly reduces LDL-C in patients with high cardiovascular risk
Allo-iNKT cell therapy shows durable survival and immune restoration in PD-1–refractory tumours
New treatment option offers hope for children with nephropathic cystinosis
Lead ATAC candidate HDP-101 shows strong clinical activity and safety in phase 8 cohort
Real-time process mapping cuts manual workload and boosts frontline efficiency
CGT Catapult annual review shows sector’s impact on economy and patient access
Early treatment with vamorolone shows sustained efficacy and improved safety profile
Deal strengthens CNS portfolio and ensures continuity of access for MS patients
Three-year trial results reveal long-term improvements in pain and lesion resolution
New self-loading reagents offer unmatched flexibility for immunologists
First-in-class mast cell selective c-Kit inhibitor enters clinical testing in Germany
SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA
Faster scans and same-day results improve patient experience across community sites
New data support European filing for nonsteroidal topical treatment
Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of...